BR112020018212A2 - Formas cristalinas de um estimulante de sgc - Google Patents

Formas cristalinas de um estimulante de sgc Download PDF

Info

Publication number
BR112020018212A2
BR112020018212A2 BR112020018212-5A BR112020018212A BR112020018212A2 BR 112020018212 A2 BR112020018212 A2 BR 112020018212A2 BR 112020018212 A BR112020018212 A BR 112020018212A BR 112020018212 A2 BR112020018212 A2 BR 112020018212A2
Authority
BR
Brazil
Prior art keywords
fluorbenzyl
pyrazine
imidazo
crystalline
triazol
Prior art date
Application number
BR112020018212-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Kwame W. Nti-Addae
Leena Kumari Prasad
Thomas Storz
Original Assignee
Cyclerion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020018212(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyclerion Therapeutics, Inc. filed Critical Cyclerion Therapeutics, Inc.
Publication of BR112020018212A2 publication Critical patent/BR112020018212A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112020018212-5A 2018-03-07 2019-03-07 Formas cristalinas de um estimulante de sgc BR112020018212A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
US62/639,846 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
BR112020018212A2 true BR112020018212A2 (pt) 2020-12-29

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020018212-5A BR112020018212A2 (pt) 2018-03-07 2019-03-07 Formas cristalinas de um estimulante de sgc

Country Status (21)

Country Link
US (3) US11466015B2 (https=)
EP (1) EP3762389B1 (https=)
JP (1) JP7423539B2 (https=)
KR (1) KR102782810B1 (https=)
CN (1) CN111836812A (https=)
AU (1) AU2019231724B2 (https=)
BR (1) BR112020018212A2 (https=)
CA (1) CA3092683A1 (https=)
CL (5) CL2020002284A1 (https=)
CO (1) CO2020012493A2 (https=)
CR (1) CR20200458A (https=)
EA (1) EA202092109A1 (https=)
ES (1) ES2980256T3 (https=)
IL (1) IL276853B1 (https=)
MA (1) MA54638A (https=)
MX (5) MX2023004857A (https=)
PE (1) PE20210124A1 (https=)
PH (1) PH12020551394A1 (https=)
SG (1) SG11202008641WA (https=)
TW (1) TWI823903B (https=)
WO (1) WO2019173551A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator
KR20250141845A (ko) * 2018-07-11 2025-09-29 티센토 쎄라퓨틱스 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
EA027909B1 (ru) 2012-11-30 2017-09-29 Астеллас Фарма Инк. Имидазопиридиновые соединения
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) * 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
SI3507291T1 (sl) * 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji
AU2019231724B2 (en) 2018-03-07 2024-06-27 Tisento Therapeutics Inc. Crystalline forms of an sGC stimulator

Also Published As

Publication number Publication date
PE20210124A1 (es) 2021-01-19
WO2019173551A8 (en) 2020-06-11
MA54638A (fr) 2021-11-10
KR102782810B1 (ko) 2025-03-14
WO2019173551A1 (en) 2019-09-12
AU2019231724A1 (en) 2020-10-08
JP7423539B2 (ja) 2024-01-29
KR20200128708A (ko) 2020-11-16
AU2019231724B2 (en) 2024-06-27
US20210115050A1 (en) 2021-04-22
MX2023004857A (es) 2023-11-24
CR20200458A (es) 2020-11-09
CL2021003536A1 (es) 2022-08-19
CL2021003530A1 (es) 2022-08-19
EP3762389B1 (en) 2024-02-28
TW201940487A (zh) 2019-10-16
CL2020002284A1 (es) 2020-11-27
MX2020009183A (es) 2020-10-08
MX2023004855A (es) 2023-11-24
US20250115611A1 (en) 2025-04-10
US11466015B2 (en) 2022-10-11
SG11202008641WA (en) 2020-10-29
JP2021515015A (ja) 2021-06-17
EP3762389A1 (en) 2021-01-13
TWI823903B (zh) 2023-12-01
EA202092109A1 (ru) 2021-03-04
CL2021000301A1 (es) 2021-06-18
MX2023004858A (es) 2023-11-24
CA3092683A1 (en) 2019-09-12
CO2020012493A2 (es) 2020-10-30
US12122782B2 (en) 2024-10-22
CN111836812A (zh) 2020-10-27
CL2021003531A1 (es) 2022-08-19
IL276853B1 (en) 2026-01-01
IL276853A (en) 2020-10-29
ES2980256T3 (es) 2024-09-30
MX2023004856A (es) 2023-11-24
PH12020551394A1 (en) 2021-11-22
US20230095799A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US12122782B2 (en) Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
US20240059683A1 (en) Solid forms of an sgc stimulator
BR112020012629A2 (pt) estimulantes de sgc
HK40042071A (en) Crystalline forms of an sgc stimulator
HK40042071B (en) Crystalline forms of an sgc stimulator
EA048931B1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC
CA3029333C (en) Solid forms of an sgc stimulator
WO2021195403A1 (en) Deuterated sgc stimulators
EA045683B1 (ru) ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC
HK40007030A (en) Solid forms of an sgc stimulator
HK40007030B (en) Solid forms of an sgc stimulator
OA19465A (en) Solid forms of an SGC stimulator.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]